Suture Length Effects in Acupoint Implantation for Abdominal Obesity

Chang Gung Medical Foundation

Status: Active, not recruiting

Conditions: Abdominal Obesity; Obesity

Treatments: Device: 1 inch; Device: 0.5 inch

Study type: Interventional

Funder types: Other

Identifiers

NCT07125716

202500161A3

Details and patient eligibility

About

Obesity is a metabolic disorder and has become a global health issue with a steadily increasing prevalence. According to the Health Promotion Administration's statistical report, the overweight and obesity rate among adults in Taiwan was 50.3% between 2017 and 2020. Based on the Ministry of Health and Welfare's criteria, a BMI ≥27 kg/m² is classified as obese.

Studies have shown that acupuncture can effectively reduce body weight with low cost and minimal side effects. Acupoint catgut embedding is a treatment method that combines traditional meridian acupuncture with modern medical materials by implanting surgical sutures into acupoints to provide continuous stimulation.

A 2022 systematic review found that catgut embedding is more effective than traditional acupuncture, requires fewer treatment sessions, and has a high safety profile. However, no studies have yet investigated whether different lengths of implanted surgical sutures affect treatment outcomes.

This study is a single-center, double-blind, randomized controlled trial aimed at identifying the optimal suture length for acupoint catgut embedding, in order to enhance its efficiency and therapeutic effect.

Enrollment: 78 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Willing to sign a written informed consent form
2. BMI ≥27 kg/m² (Ministry of Health and Welfare standard)
3. Waist circumference ≥90 cm for men
4. Waist circumference ≥80 cm for women
5. Age between 18 and 65 years

Exclusion criteria

1. Endocrine disorders (thyroid disease, pituitary disorders, and diabetes)
2. Autoimmune diseases (systemic lupus erythematosus, Sjögren's syndrome, and rheumatoid arthritis)
3. Heart diseases (heart failure, arrhythmia, etc.)
4. Abnormal liver function
5. Abnormal kidney function
6. Stroke within the past year
7. Pregnant or breastfeeding women
8. Coagulation disorders
9. Tumors
10. Participation in weight loss treatment within the past 6 months
11. Any other condition deemed unsuitable for the trial by the physician

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

78 participants in 2 patient groups

1 inch suture length

Experimental group

Treatment:

Device: 1 inch

0.5 inch suture length

Active Comparator group

Treatment:

Device: 0.5 inch